Creative Biolabs, a global Contract Research Organization (CRO), has announced the launch of its integrated, one-stop antisense oligonucleotide (ASO) development services. The platform aims to address technical bottlenecks that often slow the translational development of RNA therapeutics, including designing candidates with high binding affinity, overcoming in vivo enzymatic degradation, and achieving tissue-specific delivery.
Traditional ASO development is often fragmented, requiring researchers to coordinate with multiple vendors for design, synthesis, and animal testing, leading to extended timelines and data inconsistency. Creative Biolabs' new service unifies the entire pipeline under one roof, offering proprietary bioinformatic optimization, advanced chemical modification and synthesis, precision delivery and conjugation, and robust preclinical validation.
The bioinformatic optimization utilizes thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions, mitigating off-target risks from the outset. Chemical modification capabilities include versatile oligonucleotide architectures such as Gapmers and steric-blocking oligos, with production scales from milligram to multi-gram. Modifications like PS backbones, PMO, and sugar modifications (2'-MOE, cEt) improve nuclease resistance and support in vivo stability.
To address cellular uptake barriers, Creative Biolabs offers custom targeted delivery technologies, including GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations. Preclinical validation encompasses in vitro screening (mRNA knockdown via qPCR, cytotoxicity testing) and in vivo PK/PD profiling to support candidate selection and development planning.
“Many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability,” stated the Chief Scientific Officer at Creative Biolabs. “Our one-stop platform eliminates these silos. By matching customized chemical modifications with precise conjugation chemistries early in the design phase, we significantly lower required doses and improve the safety profiles of our clients' candidates.”
The company also offers a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, providing flexibility and technical expertise to turn therapeutic concepts toward preclinical candidate development.
This announcement is significant for the RNA therapeutics industry as it addresses core hurdles that have historically hindered ASO development. By offering an integrated service, Creative Biolabs enables researchers to streamline their workflows, reduce timelines, and improve data consistency. The platform's focus on early-stage optimization of chemical modifications and delivery methods could lower doses and enhance safety profiles, potentially accelerating the development of new treatments for genetic disorders, cancers, and neuromuscular diseases. For the broader biopharmaceutical community, this service may reduce the risk of late-stage failures and facilitate the translation of ASO candidates into clinical trials.
